After this, Musk said in a podcast in August that the second patient’s BCI implant was functioning properly. Within the year, Neuralink intends to implant the device in eight additional patients and greatly expand its clinical trials. A crucial first step in confirming the technology’s efficacy and safety on a broader scale is this expansion.
Neuralink expands trials
Neuralink is expanding its BCI research beyond the US. Following approval for a feasibility study on using its N1 Implant to control an assistive robotic arm, the company announced its first international trial.
In November, Neuralink also received Health Canada’s approval for the CAN-PRIME Study, now open to Canadian nationals.